CFD 属于复杂的高风险金融工具，其杠杆作用可能导致投资者迅速亏损。 84% 的散户投资者因进行 CFD 交易遭受资金损失。 请您谨慎考虑自己是否了解 CFD 操作，以及是否能够接受高额亏损的风险。
Country • United States
    Entity • country not supported, please select another country
    English العَرَبِيَّة Bahasa Indonesia Български Čeština Dansk Deutsch Eesti ελληνικά Español Français Hrvatski Italiano Latviešu Lietuvių Magyar Nederlands Polski Português Română Русский Slovenčina Slovenščina Suomi Svenska Tiếng Việt ไทย 简体中文 繁體中文

    交易 Eledon Pharmaceuticals, Inc. - ELDN CFD

    -
    0%
    • 概括
    • 历史数据
    • 活动
    • 收入报表
    • 资产负债表
    • 现金流
    • 所有权
    交易条件
    价差 -
    多头隔夜费

    Long position overnight fee

    Margin. Your investment $1,000.00
    隔夜费用 -0.024874 %
    Charges from borrowed part ($-0.99)
    Trade size with leverage ~ $5,000.00
    Money from leverage ~ $4,000.00
    前往平台
    		-0.024874%
    空头隔夜费

    Short position overnight fee

    Margin. Your investment $1,000.00
    隔夜费用 0.002651 %
    Charges from borrowed part ($0.11)
    Trade size with leverage ~ $5,000.00
    Money from leverage ~ $4,000.00
    前往平台
    		0.002651%
    隔夜费时间 21:00 (UTC)
    最小交易量 1
    货币 USD
    保证金 20%
    上市交易所 United States of America
    交易费 0%

    *Information provided by Capital.com

    关键数据
    前收盘价* N/A
    开盘价* N/A
    1 年变化* N/A
    日范围* N/A
    52 周范围 1.90-4.15
    平均交易量（10 天） 33.27K
    平均交易量（3 个月) 454.10K
    市值 32.26M
    市盈率 -100.00K
    流通股 13.76M
    收入 N/A
    EPS -2.66
    股息（收益率 %） N/A
    贝塔 2.13
    下一个财报发布日期 Mar 30, 2023

    所有数据都是由Refinitiv提供的， 除了标有星号的数据， 这是*由 Capital.com 提供的数据

    • Last Week
    • Last Month
    • Last Year
    • Last two Years
    • Max
    • Daily
    • Weekly
    • Monthly
    Date 平倉 Change Change (%) 開倉 High Low

    Eledon Pharmaceuticals, Inc. Events

    時間（協調世界時） (UTC) 國家 事件
    No events scheduled
    查看所有活動
    • 年度
    • 每季度
    2021 2020 2019 2018 2017
    总收入 0 0 0 0 0
    收入
    总营业费用 36.867 18.465 16.051 14.06 13.121
    销售/一般/行政费用，总计 13.132 10.052 6.056 7.243 11.099
    研究与开发 23.735 6.131 8.128 6.817 2.022
    营业收入 -36.867 -18.465 -16.051 -14.06 -13.121
    利息收入（费用），非经营净值
    税前净收入 -36.86 -23.215 -16.011 -14.065 -13.116
    税后净收入 -34.506 -22.811 -16.011 -14.065 -13.116
    未计算非常项目前的净收益 -34.506 -22.811 -16.011 -14.065 -13.116
    净收入 -34.506 -22.811 -16.011 -14.065 -13.116
    普通股股东可获收益 (不含非经常性项目) -34.506 -22.811 -16.011 -14.065 -13.116
    普通股股东可获收益 (含非經常性項目) -34.506 -22.811 -16.011 -14.065 -13.116
    摊薄净收入 -34.506 -22.811 -16.011 -14.065 -13.116
    摊薄后加权平均股 14.8196 1.45143 0.65558 0.50034 0.25989
    扣除特别项目的每股摊薄盈利 -2.32841 -15.7162 -24.4227 -28.111 -50.4679
    每股正常摊薄盈利 -2.32841 -14.6943 -21.5748 -28.111 -50.4679
    其他，净值 0.007 -4.75 0.04 -0.005 0.005
    非常规项目总计 0
    异常费用（收入） 0 2.282 1.867
    Sep 2022 Jun 2022 Mar 2022 Dec 2021 Sep 2021
    总收入 0 0 0 0 0
    总营业费用 10.598 9.283 9.859 9.385 10.506
    销售/一般/行政费用，总计 3.146 3.54 3.224 3.203 2.848
    研究与开发 7.452 5.743 6.635 6.182 7.658
    营业收入 -10.598 -9.283 -9.859 -9.385 -10.506
    其他，净值 0.127 0.036 -0.005 0 0.003
    税前净收入 -10.471 -9.247 -9.864 -9.385 -10.503
    税后净收入 -10.471 -9.247 -9.864 -8.806 -9.817
    未计算非常项目前的净收益 -10.471 -9.247 -9.864 -8.806 -9.817
    净收入 -10.471 -9.247 -9.864 -8.806 -9.817
    普通股股东可获收益 (不含非经常性项目) -10.471 -9.247 -9.864 -8.806 -9.817
    普通股股东可获收益 (含非經常性項目) -10.471 -9.247 -9.864 -8.806 -9.817
    摊薄净收入 -10.471 -9.247 -9.864 -8.806 -9.817
    摊薄后加权平均股 14.2659 14.2659 14.3307 14.8159 14.8159
    扣除特别项目的每股摊薄盈利 -0.73399 -0.64819 -0.68831 -0.59436 -0.6626
    Dividends per Share - Common Stock Primary Issue 0 0 0 0
    每股正常摊薄盈利 -0.73399 -0.64819 -0.68831 -0.59436 -0.6626
    异常费用（收入） 0 0
    • 年度
    • 每季度
    2021 2020 2019 2018 2017
    流动资产总额 88.346 115.63 9.971 14.276 19
    现金和短期投资 84.833 114.195 8.791 12.972 17.233
    现金等价物 84.833 114.195 8.791 12.972 17.233
    短期投资
    Prepaid Expenses 3.479 1.287 0.881 0.674 1.697
    Other Current Assets, Total 0.034 0.038 0.054 0.63 0.07
    Total Assets 170.548 197.185 10.931 17.026 20.892
    Property/Plant/Equipment, Total - Net 0.768 0.138 0.321 0.014 0.025
    Property/Plant/Equipment, Total - Gross
    Accumulated Depreciation, Total
    Other Long Term Assets, Total 0.4 0.383 0.639 0.869 0
    Total Current Liabilities 4.401 2.483 1.322 2.534 1.44
    Accounts Payable 1.813 1.366 0.329 0.689 0.418
    Accrued Expenses 2.588 1.117 0.993 1.845 1.022
    Notes Payable/Short Term Debt 0 0 0 0 0
    Total Liabilities 6.553 6.589 1.466 2.534 1.44
    Total Long Term Debt 0 0 0 0 0
    Long Term Debt
    Total Equity 163.995 190.596 9.465 14.492 19.452
    Redeemable Preferred Stock 0 0 0
    Common Stock 0.014 0.015 0.013 0.009 0.007
    Additional Paid-In Capital 278.88 270.974 67.034 56.054 46.951
    Retained Earnings (Accumulated Deficit) -114.899 -80.393 -57.582 -41.571 -27.506
    Other Equity, Total
    Total Liabilities & Shareholders’ Equity 170.548 197.185 10.931 17.026 20.892
    Total Common Shares Outstanding 14.3068 15.1604 0.72047 0.52349 0.39505
    Goodwill, Net 48.648 48.648 0 1.867 1.867
    应收账款总额，净额 0 0.11 0.245
    Other Liabilities, Total 0.4 0 0.144
    Intangibles, Net 32.386 32.386
    Deferred Income Tax 1.752 4.106
    Total Preferred Shares Outstanding 0.11427 0.10807
    Mar 2022 Dec 2021 Sep 2021 Jun 2021 Mar 2021
    流动资产总额 79.325 88.346 95.558 102.582 110.241
    现金和短期投资 76.677 84.833 94.041 101.133 108.579
    现金等价物 76.677 84.833 94.041 101.133 108.579
    应收账款总额，净额 0 0 0.087 0.197
    Prepaid Expenses 2.631 3.479 1.506 1.351 1.439
    Other Current Assets, Total 0.017 0.034 0.011 0.011 0.026
    Total Assets 161.378 170.548 177.17 184.305 191.682
    Property/Plant/Equipment, Total - Net 0.675 0.768 0.222 0.267 0.092
    Goodwill, Net 48.648 48.648 48.648 48.648 48.648
    Intangibles, Net 32.386 32.386 32.386 32.386 32.386
    Other Long Term Assets, Total 0.344 0.4 0.356 0.422 0.315
    Total Current Liabilities 2.958 4.401 4.046 2.677 4.206
    Accounts Payable 1.026 1.813 1.598 0.857 1.514
    Accrued Expenses 1.932 2.588 2.448 1.82 2.692
    Notes Payable/Short Term Debt 0 0 0 0 0
    Total Liabilities 5.06 6.553 6.422 5.784 7.811
    Total Long Term Debt 0 0 0 0 0
    Deferred Income Tax 1.752 1.752 2.331 3.017 3.605
    Total Equity 156.318 163.995 170.748 178.521 183.871
    Common Stock 0.014 0.014 0.014 0.014 0.014
    Additional Paid-In Capital 281.067 278.88 276.827 274.783 272.749
    Retained Earnings (Accumulated Deficit) -124.763 -114.899 -106.093 -96.276 -88.892
    Total Liabilities & Shareholders’ Equity 161.378 170.548 177.17 184.305 191.682
    Total Common Shares Outstanding 13.7568 14.3068 14.3068 14.3066 14.3066
    Total Preferred Shares Outstanding 0.12417 0.11427 0.11427 0.11427 0.11427
    Other Liabilities, Total 0.35 0.4 0.045 0.09
    • 年度
    • 每季度
    2021 2020 2019 2018 2017
    净收入/起跑线 -34.506 -22.811 -16.011 -14.065 -13.116
    经营活动产生的现金 -28.913 -15.212 -13.857 -11.893 -14.941
    经营活动产生的现金 0 0.005 0.009 0.011 0.022
    非现金物品 8.099 8.178 3.348 1.543 0.628
    营运资金的变化 -0.152 -0.18 -1.203 0.618 -2.475
    投资活动产生的现金 0 11.035 0 23.258
    资本支出
    其他投资现金流量项目，总计 0 11.035 0 23.258
    融资活动产生的现金 -0.449 109.581 9.676 7.562 7.869
    融资现金流项目 -0.45 -0.025
    股票的发行（报废），净额 0.001 109.606 9.676 7.562 7.869
    债务的发行（退还），净额
    现金净变化 -29.362 105.404 -4.181 -4.331 16.186
    Deferred Taxes -2.354 -0.404
    Mar 2022 Dec 2021 Sep 2021 Jun 2021 Mar 2021
    Net income/Starting Line -9.864 -34.506 -25.7 -15.883 -8.499
    Cash From Operating Activities -8.156 -28.913 -19.705 -12.612 -5.166
    Cash From Operating Activities 0 0 0 0
    Deferred Taxes 0 -2.354 -1.775 -1.089 -0.501
    Non-Cash Items 2.279 8.099 5.985 3.898 1.82
    Changes in Working Capital -0.571 -0.152 1.785 0.462 2.014
    Cash From Financing Activities 0 -0.449 -0.449 -0.45 -0.45
    Financing Cash Flow Items 0 -0.45 -0.45 -0.45 -0.45
    Issuance (Retirement) of Stock, Net 0.001 0.001 0 0
    Net Change in Cash -8.156 -29.362 -20.154 -13.062 -5.616
    Cash From Investing Activities 0 0
    Other Investing Cash Flow Items, Total 0 0
    投资者名称 投资者类型 流通股百分比 持有股份 股份变动 持有日期 换手率
    BVF Partners L.P. Hedge Fund 16.9132 2326710 0 2022-12-31 LOW
    ALS Therapy Development Institute Corporation 9.6359 1325585 0 2022-03-31 LOW
    Cormorant Asset Management, LP Hedge Fund 8.853 1217882 -5618 2022-12-31 MED
    The Vanguard Group, Inc. Investment Advisor/Hedge Fund 4.9398 679557 314 2022-12-31 LOW
    Woodline Partners LP Hedge Fund 3.7558 516675 0 2022-12-31 HIGH
    Medical Strategy GmbH Investment Advisor 3.4338 472383 0 2022-09-30 LOW
    Ensign Peak Advisors, Inc. Foundation 3.2202 443001 355715 2022-12-31 LOW
    CM Management, LLC Investment Advisor 1.7068 234800 -10200 2022-12-31 MED
    Ikarian Capital LLC Hedge Fund 1.6125 221830 0 2022-12-31 HIGH
    Geode Capital Management, L.L.C. Investment Advisor/Hedge Fund 0.9388 129151 -314 2022-12-31 LOW
    ACCI Capital Investments SGIIC, SA Investment Advisor 0.4361 60000 0 2022-12-31 LOW
    JMAC Enterprises LLC Investment Advisor 0.3964 54538 0 2022-12-31 LOW
    Ingalls & Snyder LLC (Asset Management) Investment Advisor/Hedge Fund 0.3696 50849 -300 2022-12-31 LOW
    BlackRock Institutional Trust Company, N.A. Investment Advisor 0.3569 49095 532 2022-12-31 LOW
    Two Sigma Investments, LP Hedge Fund 0.3434 47237 -24700 2022-12-31 HIGH
    State Street Global Advisors (US) Investment Advisor/Hedge Fund 0.3249 44692 0 2022-12-31 LOW
    SVB Financial Group Holding Company 0.2952 40613 40613 2022-12-31 LOW
    Northern Trust Investments, Inc. Investment Advisor/Hedge Fund 0.2185 30053 0 2022-12-31 LOW
    Renaissance Technologies LLC Hedge Fund 0.2157 29673 -2200 2022-12-31 HIGH
    Boothbay Fund Management, LLC Investment Advisor/Hedge Fund 0.1603 22050 0 2022-12-31 HIGH

    为什么选择 Capital.com？让我们的数字来说话。

    Capital.com Group

    500K+

    交易者

    92K+

    每月活跃客户

    $53M+

    每月投资额

    $30M+

    每月提取金额

    交易計算器

    如果您在特定日期（选择一个日期）开立差价合约交易并在不同日期（选择一个日期）关闭交易，计算您的假设盈亏。

    貿易佣金
    0
    • 1:1
    杠杆
    1:1
    • 20
    • 100
    • 500
    • 1000
    • 10000
    投資
    交易規模（槓桿 x 投資）：
    開倉

    平倉

    做空 做多
    過去的表現並不是未來結果的可靠指標
    盈利/失利

    Eledon Pharmaceuticals, Inc. Company profile

    关于 Eledon Pharmaceuticals Inc.

    Eledon Pharmaceuticals, Inc.是一家处于临床阶段的生物制药公司。 公司专注于为需要器官或细胞移植的自身免疫性疾病患者或肌萎缩性侧索硬化症（ALS）患者开发药物。 公司的主要候选产品AT-1501是一种人源化单克隆抗体（mAb），旨在靶向CD40配体（CD40L），也叫CD154，是一种表达在人类免疫系统T细胞表面的分子。 CD40或CD40L信号在产生促炎症反应中的核心作用使其成为治疗干预自身免疫性疾病、诱导和维持移植耐受和神经炎症的候选药物。 阻断CD40L通路的激活可以防止多种动物物种的急性和长期异体移植排斥反应，并改善自身免疫和ALS的临床前模型的疾病进展和病理情况。

    Industry: Bio Therapeutic Drugs

    19900 MacArthur Blvd Ste 550
    IRVINE
    CALIFORNIA 92612-8426
    US

    收入报表

    • Annual
    • Quarterly

    人们也观看

    XRP/USD

    0.54 Price
    -1.920% 1D Chg, %
    多头隔夜费 -0.0753%
    空头隔夜费 0.0069%
    隔夜费时间 21:00 (UTC)
    价差 0.00416

    Gold

    1,981.58 Price
    +0.880% 1D Chg, %
    多头隔夜费 -0.0180%
    空头隔夜费 0.0098%
    隔夜费时间 21:00 (UTC)
    价差 0.30

    US100

    12,964.10 Price
    +0.970% 1D Chg, %
    多头隔夜费 -0.0249%
    空头隔夜费 0.0027%
    隔夜费时间 21:00 (UTC)
    价差 1.8

    Oil - Crude

    74.38 Price
    +2.000% 1D Chg, %
    多头隔夜费 -0.0170%
    空头隔夜费 -0.0049%
    隔夜费时间 21:00 (UTC)
    价差 0.03

    还在找一位您可以信任的经纪商吗？

    加入成为全球500,000万多名交易者的一份子，选择利用Capital.com进行交易吧。

    1. 创建和验证您的账户 2. 进行存款 3. 找到适合您的交易